Thera-SAbDab

ISATUXIMAB

> Structural Summary

Therapeutic	Isatuximab
Target	CD38
Heavy Chain	QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS
Light Chain	DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK
100% seqID Fv Structure	4cmh [Fvs: BC]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4cmh [Fvs: BC]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Preregistration
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2014
INN Year Recommended	2015
Companies Involved	ImmunoGen, Huntsman Cancer Institute, Roche, Sanofi
Conditions Approved	na
Conditions Active	Multiple myeloma, Acute myeloid leukaemia, Precursor cell lymphoblastic leukaemia-lymphoma, T-cell lymphoma, Colorectal cancer, Diffuse large B cell lymphoma, Hodgkin's disease, Non-small cell lung cancer, Peripheral T-cell lymphoma, Prostate cancer, Solid tumours, Urogenital cancer
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]